KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Expenditures (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of Capital Expenditures data on record, last reported at -$12000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 146.15% year-over-year to -$12000.0; the TTM value through Dec 2025 reached $276000.0, up 9.52%, while the annual FY2024 figure was $36000.0, N/A changed from the prior year.
  • Capital Expenditures reached -$12000.0 in Q4 2025 per RIGL's latest filing, down from $26000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $407000.0 in Q2 2021 and bottomed at -$36000.0 in Q2 2022.
  • Average Capital Expenditures over 4 years is $109100.0, with a median of $72000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 1025.0% in 2021, then tumbled 146.15% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$21000.0 in 2021, then surged by 447.62% to $73000.0 in 2022, then crashed by 64.38% to $26000.0 in 2024, then crashed by 146.15% to -$12000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$12000.0 in Q4 2025, $26000.0 in Q4 2024, and $73000.0 in Q4 2022.